Nutritional Advice El Mondo
Objectives:
Do rheumatic diseases increase COVID-19 severity and fatality?
Study design:
This review article included 31 articles involving 1,138 COVID-19 patients.
The publications were from Europe, Asia and North America, but none from other continents.
There were 10 studies which only included hospitalized patients.
About 64% of the patients were female.
There was no publication bias.
Results and conclusions:
The investigators found the overall rates of hospitalization, oxygen support, ICU admission and fatality among COVID-19 infected patients with rheumatic diseases were 0.58 [95% CI = 0.48 to 0.67], 0.33 [95% CI = 0.21 to 0.47], 0.09 [95% CI = 0.05 to 0.15] and 0.07 [95% CI = 0.03 to 0.11], respectively.
The investigators found the rate of oxygen support in Europe [0.48, 95% CI = 0.4 to 0.57] was higher than that in other continents.
The investigators found among all hospitalized patients, the rates of oxygen support, ICU admission and fatality were 0.61 [95% CI = 0.48 to 0.73], 0.13 [95% CI = 0.07 to 0.21] and 0.13 [95% CI = 0.09 to 0.18], respectively.
The investigators found the fatality rate was highest in Europe [0.19, 95% CI = 0.15 to 0.24].
The investigators found the fatality rate was higher both in this meta-analysis and the COVID-19 GRA [7.0% and 6.7%, respectively] than that [3.4%] in WHO database, although the age, gender and comorbidity were not matched.
The investigators concluded COVID-19 patients with rheumatic diseases remain vulnerable, given the significant rates of ICU admission with a high risk of fatality. More studies were urgently needed to elucidate the risk factors of severe outcomes in this population.
Original title:
Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data by Xu C, Yi Z, […], Mu R.
Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889462/
Additional information of El Mondo:
Find more information/studies on corona virus right here.